ATE414080T1 - Synthese von antidiabetischen rosiglitazonderivaten - Google Patents

Synthese von antidiabetischen rosiglitazonderivaten

Info

Publication number
ATE414080T1
ATE414080T1 AT05740577T AT05740577T ATE414080T1 AT E414080 T1 ATE414080 T1 AT E414080T1 AT 05740577 T AT05740577 T AT 05740577T AT 05740577 T AT05740577 T AT 05740577T AT E414080 T1 ATE414080 T1 AT E414080T1
Authority
AT
Austria
Prior art keywords
rosiglitazone
antidiabetic
synthesis
derivatives
pharmaceutically acceptable
Prior art date
Application number
AT05740577T
Other languages
English (en)
Inventor
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of ATE414080T1 publication Critical patent/ATE414080T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
AT05740577T 2004-05-05 2005-05-03 Synthese von antidiabetischen rosiglitazonderivaten ATE414080T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0410013A GB2413795A (en) 2004-05-05 2004-05-05 Process for the preparation of rosiglitazone

Publications (1)

Publication Number Publication Date
ATE414080T1 true ATE414080T1 (de) 2008-11-15

Family

ID=32482705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05740577T ATE414080T1 (de) 2004-05-05 2005-05-03 Synthese von antidiabetischen rosiglitazonderivaten

Country Status (14)

Country Link
US (1) US7598387B2 (de)
EP (1) EP1756099B1 (de)
JP (1) JP2007536358A (de)
KR (1) KR20070014191A (de)
AT (1) ATE414080T1 (de)
AU (1) AU2005238282A1 (de)
CA (1) CA2565665A1 (de)
DE (1) DE602005011004D1 (de)
ES (1) ES2315867T3 (de)
GB (1) GB2413795A (de)
NZ (1) NZ551126A (de)
PT (1) PT1756099E (de)
WO (1) WO2005105794A1 (de)
ZA (1) ZA200609147B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2011163594A2 (en) * 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP5546372B2 (ja) * 2010-06-30 2014-07-09 積水メディカル株式会社 ベンジルヒダントイン化合物の製造法
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
EP3718536A1 (de) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit verbesserter lagerstabilität
EP3119399A4 (de) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazolformulierungen mit erhöhten injektionsgeschwindigkeiten
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
ES2007537A6 (es) 1988-07-21 1989-06-16 Cenavisa S A Procedimiento para la preparacion de derivados neutronsolubles de la sulfametoxipiridazina y del sulfametoxazol a partir de aldehidos aromaticos.
ATE267209T1 (de) 1998-05-05 2004-06-15 Lilly Co Eli Reinigung von carboxaldehyd
HU225919B1 (en) * 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
WO2002051823A1 (en) * 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate

Also Published As

Publication number Publication date
GB2413795A (en) 2005-11-09
EP1756099B1 (de) 2008-11-12
PT1756099E (pt) 2009-02-03
WO2005105794A1 (en) 2005-11-10
US20070191611A1 (en) 2007-08-16
JP2007536358A (ja) 2007-12-13
ES2315867T3 (es) 2009-04-01
EP1756099A1 (de) 2007-02-28
KR20070014191A (ko) 2007-01-31
NZ551126A (en) 2010-10-29
AU2005238282A1 (en) 2005-11-10
CA2565665A1 (en) 2005-11-10
US7598387B2 (en) 2009-10-06
GB0410013D0 (en) 2004-06-09
ZA200609147B (en) 2007-06-27
DE602005011004D1 (de) 2008-12-24

Similar Documents

Publication Publication Date Title
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
DE602005011004D1 (de) Synthese von antidiabetischen rosiglitazonderivaten
EP1541561A4 (de) Pyrazolderivate und verfahren zu deren herstellung
HUP0103988A2 (en) New d3-dopamine receptor selective piperazine and piperidine compounds, process for their preparation, their and pharmaceutical compositions containing them
IL180985A0 (en) N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methanesulfonic acid salt
ZA200710145B (en) Method for the production of 5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl-benzofuran-2-carboxamide
NO20073701L (no) Nye fremgangsmater for fremstilling av et 2H-kromen
CA2437501A1 (en) Process for the manufacture of phenylacetic acid derivatives
BRPI0516904A (pt) processo para a preparação de um derivado de 2-etilaminopiridina e composto
WO2008074693A3 (en) Process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone
UY24886A1 (es) Tiazolidindiona
WO2005012227A3 (en) Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
WO2004039776A3 (en) A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives
NO20064884L (no) Kjemisk fremgangsmate og ny krystallinsk form
NO20010265D0 (no) 3-(1-hydroksy-pentyliden)-5-nitro-3H-benzofuran-2-on, fremgangsmåte for fremstilling og anvendelse derav
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
HU0304096D0 (en) Process for the production of pioglitazone hydrogenchloride
DK1948626T3 (da) Fremgangsmåde til fremstilling af delmopinol og derivater deraf
DK1877370T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
BRPI0607085A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes
DK1465917T3 (da) Mellemprodukter for LHRH-antagonistsyntesen, fremgangsmåder til deres fremstilling samt fremgangsmåder til fremstilling af LHRH-antagonister
EA200300771A1 (ru) Новая соль бензоилгуанидина
DE602005025150D1 (de) Par-2-antagonisten
EA200900052A1 (ru) Способ синтеза основания бензилиден-росиглитазона

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties